Navigation Links
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
Date:5/7/2009

ly removed and/or have already spread to other parts of the body (metastasised). In Japan, Glivec is approved for the treatment of patients with KIT (CD117)-positive GIST. In the EU, Glivec is also approved for the treatment of adult patients with newly diagnosed Ph+ acute lymphoblastic leukaemia (Ph+ ALL) in combination with chemotherapy and as a single agent for patients with relapsed or refractory Ph+ ALL. Glivec is also approved for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) who are not eligible for surgery. Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for hypereosinophilic syndrome and/or chronic eosinophilic leukaemia (HES/CEL).

    Not all indications are available in every country.
    For summary of product characteristics, please see:
   http://emc.medicines.org.uk/document.aspx?documentId=15014
    About Novartis

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 96,700 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit

SOURCE Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
2. Bionovo Announces First Quarter 2009 Highlights and Financial Results
3. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
4. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
5. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
6. Transcept Pharmaceuticals to Report First Quarter 2009 Results
7. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
9. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
10. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
11. Oakwood Surgeons Perform Worlds First 3D Surgery Without Special Glasses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has ... (London, UK - November 16-18, 2015)" conference to their offering. ... including Columbia, Peru , Brazil ... Uruguay , Paraguay , ... , Chile This seminar can ...
(Date:9/2/2015)... -- Seeger Weiss LLP is reporting that Zimmer Holdings Inc.,s ... 2015. Since the product was approved ... NexGen knee implant surpassed FDA investigation and mandatory product ... that the product is substantially similar to a preexisting ... In 2001, Zimmer began distributing High ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "Medical Device Studies: Clinical Evidence ... to their offering. This course ... involved in gathering clinical evidence required for medical ... required for all medical devices and the emphasis ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... Potential New Approach for the Treatment of Inflammatory ... ... Million Payment from Partner GlaxoSmithKline, MOUNTAIN VIEW, Calif., May 13 ... trial of CCX354, an,orally-available, novel small molecule compound designed to specifically,target ...
... FRANCISCO, Calif., May 12 Napo,Pharmaceuticals, Inc., (LSE: ... in collaboration with QualityMetric, Inc. describing the development,of ... Health-Related,Quality of Life (HR-QoL) aspects of chronic diarrhea ... Society for Pharmacoeconomics and,Outcomes Research (ISPOR) Annual Meeting ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Napo Presents at ISPOR Meeting in Toronto 2
(Date:9/3/2015)... ... ... Mum n Me is pleased to announce the launch of its ... maximum protection from sun exposure, wind, bugs, and germs. The Mum n Me Baby ... keeping the cover securely in place. The new car seat cover is made with ...
(Date:9/3/2015)... ... September 03, 2015 , ... When looking at the types of people who have ... of two categories: those that have a weak appetite or those that have a fast ... to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. , The ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... announced that Bob Anders and Kelley Chapman will be joining the company’s executive ... , Anders has over 30 years’ experience in healthcare product and project ...
(Date:9/2/2015)... Basalt, Colorado (PRWEB) , ... September 03, 2015 , ... ... to its wellness services - two retreats geared towards kick-starting and inspiring wellness in ... "We love being a part of developing a whole mind-body approach to fitness - ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors of ... servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had the ... the magazine to tap the National League for Nursing’s outspoken CEO, Beverly ...
Breaking Medicine News(10 mins):Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3
... lawyers' access to a high-profile detainee at Guantanamo Bay, ... security secrets" whose revelation could "cause extremely grave damage", ... prisoners at secret CIA prisons must not be allowed ... - even to their lawyers, the Post reported.,A lawyer ...
... Researchers want doctors to be ready to handle medical problems ... it. //In the present state, what happens when a person ... get back to normal conditions for treatment in time simply ... findings from a UF study show there is little difference ...
... the trans-fat controversy for quite a while, has decided to ... oils! This is perhaps the last nail in the coffin! ... have already communicated their intention of banishing trans fats from ... Government to bring in a law that would entail manufacturers ...
... leading economic think tank has urged policymakers to ensure ... women to reduce their// economic and social vulnerability., ... disproportionately affected by HIV and AIDS get equal opportunities ... Economic Research (NCAER) in a report on 'Gender impact ...
... against time to prevent HIV, the virus that causes AIDS, ... in// the number of prostitutes and lack of safe sex ... three-year programme to encourage the use of condoms and voluntary ... UNAIDS estimates 500 HIV-infected people in Bhutan, a country of ...
... battled off the infection appear to be shielded from ... Canadian study.// ,WebMD.com said that Drug users ... British Columbia researchers for presence of Hepatitis C antibodies ... C mainly through their habit of sharing needles during ...
Cached Medicine News:Health News:Researchers explore medicine in space 2Health News:Researchers explore medicine in space 3Health News:Equal Opportunities For HIV-Positive Women Urged 2Health News:HIV/AIDS Epidemic Scare In Bhutan 2
... Solution For Your Tracheostomy Care Needs, ... features the latest components for efficient and ... task. Designed by clinicians, these latex-free trays ... patient and caregiver. All of our trays ...
... Medline Has the Right Solution For ... tracheostomy clean and care tray features the ... of this important infection control task. Designed ... the individual needs of each patient and ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
Medicine Products: